Isavuconazole
As of the edition of 20 October 2026, Isavuconazole is a small molecule: marketed, first approved in 2015 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Cresemba
- First approved
- 15 October 2015 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Basilea Pharmaceutica Deutschland
- Registered trials
- 41, 0 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 3 | 4 | 0 |
| Phase 1 | 26 | 24 | 2 | 0 |
| Phase 2 | 3 | 2 | 1 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 41 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Basilea Pharmaceutica Deutschland | Applicant | 2015 to now |